eMedicine Specialties > Emergency Medicine > Infectious Diseases

Condyloma Acuminata

Delaram Ghadishah, MD, Staff Physician, Encino Tarzana Emergency Department

Updated: Dec 22, 2008

Introduction

Background

Condyloma acuminatum refers to an epidermal manifestation attributed to the epidermotropic human papillomavirus (HPV). More than 100 types of double-stranded HPV papovavirus have been isolated to date. Many of these have been related directly to an increased neoplastic risk in men and women.

Approximately 90% of condyloma acuminata are related to HPV types 6 and 11. These 2 types are the least likely to have a neoplastic potential. Risk for neoplastic conversion has been determined to be moderate (types 33, 35, 39, 40, 43, 45, 51-56, 58) or high (types 16, 18), with many other isolated types. The picture is complicated by proven coexistence of many of these types in the same patient (10-15% of patients), the lack of adequate information on the oncogenic potential of many other types, and ongoing identification of additional HPV-related clinical pathology.

For example, bowenoid papulosis, seborrheic keratoses, and Buschke-Löwenstein tumors have been linked to HPV infections though they were previously a part of the differential diagnosis of condyloma acuminata. Bowenoid papulosis consists of rough papular eruptions attributed to HPV and is considered to be a carcinoma in situ. The eruptions can be red, brown, or flesh colored. They may regress or become invasive. Seborrheic keratoses previously were considered a benign skin manifestation. HPV has been linked to rough plaques indicative of this disease. It has both an infectious and an oncogenic potential. Finally, Buschke-Löwenstein tumor (ie, giant condyloma) is a fungating, locally invasive, low-grade cancer attributed to HPV.

Pathophysiology

Cells of the basal layer of the epidermis are invaded by HPV. These penetrate through skin and cause mucosal microabrasions. A latent viral phase begins with no signs or symptoms and can last from a month to several years. Following latency, production of viral DNA, capsids, and particles begins. Host cells become infected and develop the morphologic atypical koilocytosis of condyloma acuminata.

The most commonly affected areas are the penis, vulva, vagina, cervix, perineum, and perianal area. Uncommon mucosal lesions in the oropharynx, larynx, and trachea have been reported. HPV-6 even has been reported in other uncommon areas (eg, extremities).

Multiple simultaneous lesions are common and may involve subclinical states as well-differentiated anatomic sites. Subclinical infections have been established to carry both an infectious and oncogenic potential.

Consider sexual abuse as a possible underlying problem in pediatric patients; however, keep in mind that infection by direct manual contact or indirectly by fomites rarely may occur. Finally, passage through an infected vaginal canal at birth may cause respiratory lesions in infants.

Frequency

United States

Annual incidence of condyloma acuminatum is 1%. It is considered the most common sexually transmitted disease (STD). Prevalence has been reported to exceed 50%. Highest prevalence and risk is among young adults in the third decade and in older teenagers. A 4-fold or more increase in prevalence has been reported in the last 2 decades.

International

International prevalence has been reported variably. Available data from England, Panama, Italy, the Netherlands, and other developed and underdeveloped countries report HPV infections to be at least as common as in the US.

Mortality/Morbidity

• Mortality is secondary to malignant transformation to carcinoma in both males and females. This oncogenic potential has been reported to triple the risk of genitourinary cancer among infected males. Fortunately, this is rare with HPV types 6 and 11, which are the most commonly isolated viruses.
• HPV infection appears to be more common and worse in patients with various types of immunologic deficiencies. Recurrence rates, size, discomfort, and risk of oncologic progression are highest among those patients. Secondary infection is uncommon.
• Latent illness often becomes active during pregnancy. Vulvar condyloma acuminata may interfere with parturition. Trauma then may occur, producing crusting or erythema. Bleeding has been reported in large lesions that can occur during pregnancy.
• In males, bleeding has been reported due to flat warts of the penile urethral meatus, usually associated with HPV-16. Lesions may lead to disfigurement of area(s) involved. Finally, acute urethral obstruction in women also may occur.

Sex

• Both sexes are susceptible to infection.
• Overt disease may be more common in men (reported in 75% of patients); however, infection may be more prevalent in women.

Age

• Prevalence is greatest in persons aged 17-33 years, with incidence peaking in persons aged 20-24 years.

Clinical

History

• Smoking, oral contraceptives, multiple sexual partners, and early coital age are risk factors for acquiring condyloma acuminata.
• Generally, two thirds of individuals who have sexual contact with a partner with condyloma acuminata develop lesions within 3 months.
• The chief complaint usually is one of painless bumps, pruritus, or discharge.
  • Involvement of more than 1 area is common.
  • History of multiple lesions, rather than 1 isolated wart, is common.
• Oral, laryngeal, or tracheal mucosal lesions (rare) presumably are transferred by oral-genital contact.
• History of anal intercourse in both males and females warrants a thorough search for perianal lesions.
• Rarely, urethral bleeding or urinary obstruction may be the presenting complaint when the wart involves the meatus.
• The patient's history may indicate presence of previous or other current STDs.
• Coital bleeding may occur. Vaginal bleeding during pregnancy may be due to condyloma eruptions.
• Latent illness may become active, particularly with pregnancy and immunosuppression.
• Lesions may regress spontaneously, remain the same, or progress.
• Pruritus may be present.
• Discharge may be a complaint.

Physical

• Single or multiple papular eruptions may be observed.
  • Eruptions may appear pearly, filiform, fungating, cauliflower, or plaquelike.
  • They can be quite smooth (particularly on penile shaft), verrucous, or lobulated.
  • Eruptions may seem harmless or may have a disturbing appearance.
• Carefully search for simultaneously involved multiple sites.
• Eruptions' color may be the same as the skin, or they may exhibit erythema or hyperpigmentation. Check for irregularity in shape, form, or color suggestive of melanoma or malignancy.
• Propensity has been established for penile glans and shaft in men and for vulvovaginal and cervical areas in women.
  • In contrast to early reports, presence of external condyloma acuminata in both men and women warrants a thorough search for cervical or urethral lesions.
  • Such internal lesions have been found in more than one half of females with external lesions.
  • One report indicates that infected males have a 20% chance of having subclinical urethral lesions.
  • More than 50% of female patients with external lesions have been found to have negative Papanicolaou (Pap) tests but tested positive for HPV infection using in situ hybridization.
• Urethral meatus and mucosal lesions can occur.
  • Some are subclinical.
  • Hair or the inner aspect of uncircumcised foreskin hides some lesions.
• Search for evidence of other STDs (eg, ulcerations, adenopathy, vesicles, discharge).
• Look for perianal lesions, particularly in patients with history or risk of immunosuppression or anal intercourse.

Causes

• Several of the epidermotropic HPVs cause condyloma acuminata.
• HPV types 6 and 11 most commonly are isolated, but many of the more than 60 types of HPV potentially cause condyloma.
• Male sexual partners of women with cervical intraepithelial neoplasia often have infections with the same viral type.

Differential Diagnoses

Molluscum Contagiosum
Rhabdomyolysis

Other Problems to Be Considered

Bowen disease
Condyloma lata
Darier disease
Fibroepitheliomas
Hailey-Hailey disease
Neoplasia
Nevi
Pearly penile papules
Squamous cell carcinoma in situ
Vulvar neurofibromatosis
Vulvar vestibular papillae

Workup

Laboratory Studies

• As indicated by history and examination, test for other STDs, such as HIV, gonorrhea, chlamydia, and syphilis.
• Although not ED tests, the following are listed strictly for educational purposes and to assist readers in understanding and managing potential complications:
  • Pap smear: This test is used to look for papillomatosis, acanthosis, koilocytic abnormality, and mild nuclear abnormality.
  • Filter hybridization (Southern blot and slot blot hybridization), in situ hybridization, and polymerase chain reaction (PCR): These tests may be used for diagnosis and HPV typing.
  • Hybrid capture

Other Tests

• Acetowhitening
  • Subclinical lesions can be visualized by wrapping penis with gauze soaked with 5% acetic acid for 5 minutes.
  • Using a 10-X hand lens or colposcope, warts appear as tiny white papules.
  • A shiny white appearance of skin represents foci of epithelial hyperplasia (subclinical infection).

Procedures

• Although not ED procedures, the following are listed strictly for educational purposes and to assist readers in understanding and managing potential presenting complications:
  • Colposcopy (stereoscopic microscopy): This is very useful to identify (mostly) cervical lesions, which are identified better using acetic acid.
  • Biopsy: Biopsy is indicated for lesions that are atypical, recurrent after initial success, or resistant to treatment or in patients with a high risk for neoplasia or immunosuppression.
  • Anoscopy
  • Antroscopy

Treatment

Prehospital Care

Generally, prehospital care is unwarranted and inappropriate; however, reassure the patient and search for the possibility of another underlying reason prehospital care was requested.

Emergency Department Care

• Type of workup, treatment regimens, and necessary follow-up care for condyloma acuminata generally are far beyond the scope of ED practice. However, the following procedures may be implemented if indicated:
  • Use pressure to stop any bleeding.
  • Relieve urethral obstruction in rare cases.
  • Reassure the patient.
  • Search for evidence of other coexistent STDs and treat if found.
  • Do not begin treatment of condyloma in the ED.
• Although not ED treatments, the following are listed strictly for educational purposes and to assist readers in understanding and managing potential presenting complications of condyloma acuminata:
  • Cryotherapy
    • Cryotherapy may be performed using an open spray or cotton-tipped applicator for 10-15 seconds and repeated as needed. Lift away mobile skin from underlying normal tissue before freezing.
    • Cryotherapy is an excellent first-line treatment, particularly for perianal lesions.
    • Response rates are high with few adverse sequelae.
    • Adverse reactions include pain at time of treatment, erosion, ulceration, and postinflammatory hypopigmentation of skin.
    • Cryotherapy is safe during pregnancy.
  • Electrodesiccation: Smoke plume potentially may be infective.
  • Curettage
  • Surgical excision
    • Excision has highest success rate and lowest recurrence rate.
    • Initial cure rates are 63-91%.
  • Carbon dioxide laser treatment
    • Use carbon dioxide laser treatment for extensive or recurrent condyloma acuminata.
    • Potentially infectious HPV-6 DNA has been detected in the carbon dioxide laser plume.
    • Local, regional, or general anesthesia is required. Eutectic mixture of local anesthetics (EMLA) cream may be used as an alternative anesthetic.

Consultations

• No emergent ED consultation generally is indicated.
• Outpatient OB/GYN or urologic follow-up care is appropriate.

Medication

Although not ED medications, the following are listed strictly for educational purposes and to assist readers in understanding and managing potential presenting complications.

Cytotoxic agents

Inhibit proliferation of cells at various stages of the cell cycle.

Podophyllum resin (Podocon-25, Pod-Ben-25)

Extract of various plants, which are cytotoxic. Effective in arresting mitosis in metaphase. Expect cure rate of 20-50% if used as single agent.

Dosing

Adult

Concentration of 20-50% applied by physician onto lesions 1-2 times per wk; treat only intact lesions; wash treatment area 1-2 h after first application; after subsequent treatments, patient can wait 4-6 h before washing off agent
Not for application to cervix, vagina, or anal canal where the squamocolumnar junction is prone to dysplastic changes

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity; diabetes; impaired peripheral circulation; avoid use on mucous membranes, eyes, bleeding warts, moles, birthmarks, or unusual warts with hair; patients using steroids; breastfeeding

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Avoid clinically normal skin; do not use on bleeding or unusual warts or moles; highly keratinized lesions; poorly absorbed podophyllin-containing agents; may cause florid irritant dermatitis with erosions and ulceration as well as severe necrosis, scarring, and fistula-in-ano; systemic absorption from inappropriate application may cause paresthesia, paralytic ileus, polyneuritis, thrombocytopenia, pyrexia, leukopenia, coma, or death

Podofilox (Condylox)

Purified podophyllotoxin that is antimitotic, cytotoxic, and available for patient's home use. While exact mechanism of action on condyloma is unknown, podofilox results in necrosis of genital condyloma acuminata. Condylox is one agent containing podofilox. Slightly higher cure rates can be expected with podofilox than with podophyllin. Additionally, useful for prophylaxis.

Dosing

Adult

Apply 0.5% solution bid for 3 consecutive d and discontinue for 4 d, not to exceed 4 wk
Use <0.5 mL of solution or 0.5 g of gel/d; treat <10 cm² of tissue per day; wash hands thoroughly after each application

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Avoid contact with eyes; if eye contact, immediately flush eye with copious quantities of water and seek medical advice; not for use on mucous membranes of genital area including urethra, rectum and vagina; do not exceed frequency of application or duration of usage

Trichloroacetic or bichloracetic acids

At various concentrations (up to 80%), these agents rapidly penetrate and cauterize skin, keratin, and other tissues. Bichloracetic acid is one such agent. Although caustic, this treatment causes less local irritation and systemic toxicity. Additionally, has low cost. Response is often incomplete, and recurrence is frequent.

Dosing

Adult

Paint treatment onto lesions, avoiding uninvolved skin; can be used in anal area; repeat treatment q1-2wk; treatment area does not need to be cleansed after several hours

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity; not for use on premalignant or malignant lesions

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

External use only; restrict use to treatment areas only

5-Fluorouracil (Adrucil, Efudex, Fluoroplex)

No longer recommended for routine use.

Has antimetabolic and/or antineoplastic and immunostimulative activity. Useful in prevention of recurrence after condyloma ablation if started within 4 wk, especially in immunocompromised patients.

Dosing

Adult

Administer 5% cream qd or periodically for 10 wk; apply 1% cream bid for 2-6 wk; mild local discomfort can be treated with cortisol cream; topical 5-FU is best option for preventing recurrence in immunocompromised patients; in general, no systemic adverse effects exist; however, prolonged use results in erosive dermatitis and mucositis; additionally, risk of vaginal adenosis and clear cell adenocarcinoma exists

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity; potentially serious infections; not for use in women who are or who may become pregnant

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Delayed hypersensitivity reaction may occur; do not use an occlusive dressing since incidence of inflammatory reaction in adjacent skin may increase; avoid prolonged exposure to sunlight or UV radiation; increased absorption may occur through ulcerated or inflamed skin; use care near eyes, nose, and mouth; wash hands immediately after application; pain, pruritus, burning, irritation, inflammation, allergic contact dermatitis, and telangiectasia may be observed

Bleomycin (Blenoxane)

Composed of cytotoxic glycopeptide antibiotics, which appear to inhibit DNA synthesis with some evidence of RNA and protein synthesis inhibition to a lesser degree; used in management of several neoplasms as a palliative measure; may cause a variety of adverse effects; observe patients frequently and carefully during and after treatment.

Dosing

Adult

Reconstitute Blenoxane 15-U vial with 1-5 mL of sterile water or NS for injection; administer intralesionally

Pediatric

Not established

Interactions

May decrease plasma levels of digoxin and phenytoin; cisplatin may increase toxicity of bleomycin

Contraindications

Documented hypersensitivity; significant renal function impairment; compromised pulmonary function

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Bleomycin may be mutagenic; clearance may be reduced with renal impairment; may be secreted in breast milk; adverse effects include pulmonary toxicity (10%), idiosyncratic reaction similar to anaphylaxis (1%), erythema, rash, striae, vesiculation, hyperpigmentation, tenderness of skin (50%), hyperkeratosis, nail changes, alopecia, pruritus, and stomatitis

Imiquimod (Aldara)

Induces interferon production and is a cell-mediated immune response modifier. Has minimal systemic absorption but causes erythema, irritation, ulceration, and pain. Burning, erosion, flaking, edema, induration, and pigmentary changes may occur at application site.
Imiquimod 5% cream comes in single-use packets.

Dosing

Adult

Apply at bedtime for 3 d, then rest 4 d; alternatively, may apply qod for 3 applications; may repeat weekly cycles up to 16 wk
(Patients should apply thin layer to external, visible warts, then rub in cream until vanishes. Area is washed with soap and water 6-10 h after treatment.)

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Genital use: Not recommended for treatment of rectal, cervical, intravaginal, urethral, and intra-anal human papilloma infection; following surgery or drug treatment, do not use topical imiquimod until genital/perianal tissue is healed
Actinic keratosis: Avoid exposure to sunlight or artificial tanning; regular use of sunscreen is encouraged; avoid contact with lips, eyes, or nostrils; common adverse effects include erythema, edema, vesicles, erosion or ulceration, weeping, exudate, flaking, scaling, dryness, and scabbing or crusting
Basal cell carcinoma: Medical follow-up is essential to ensure cancer has responded adequately to treatment; may cause redness, swelling, and sore development at application site; may cause itching or burning

Interferons

No longer recommended for routine use.

Naturally produced proteins with antiviral, antitumor, and immunomodulatory actions. Alpha, beta, and gamma interferons exist and may be administered topically, systemically, and intralesionally. Topical, systemic, and intralesional interferons are not efficacious.

Interferon alfa-n3 (Alferon N)

Alpha interferon has been approved by FDA for injectional use in refractory condyloma acuminata with some possible benefit. Alferon N is interferon alpha-n3, which has been used effectively for this purpose.
Recurrence rate of 20-40% exists with intralesional interferon, but recurrence rate after successful treatment is lower than with other treatment modalities. Additionally, intralesional interferon is expensive and requires repeat office visits.
Furthermore, numerous adverse reactions may occur, including myalgias, fever, chills, GI symptoms, transient leukopenia, thrombocytopenia, LFT abnormalities, serum lipid abnormalities with intramuscular interferon, and theoretical risk of viral transmission with natural interferon products. Viral symptoms do abate with time, and all adverse effects resolve once therapy is stopped. Viral symptoms can be treated with acetaminophen or NSAIDs in the interim.

Dosing

Adult

Administer interferon alpha-n3 250,000 U/wart intralesionally twice/wk for up to 8 wk; not to exceed 2.5 million U per treatment session

Pediatric

<18 years: Not recommended
>18 years: Administer as in adults

Interactions

Theophylline may increase interferon alpha toxicity; cimetidine may increase antitumor effects; zidovudine and vinblastine may increase toxicity of interferon alpha

Contraindications

Documented hypersensitivity; anaphylactic sensitivity to mouse immunoglobulin, egg protein, or neomycin; cardiac or renal impairment

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in brain metastases, severe hepatic or renal insufficiencies, seizure disorders, multiple sclerosis, compromised CNS, or debilitating conditions (eg, cardiovascular disease, severe pulmonary disease, diabetes mellitus with ketoacidosis, coagulation disorders, severe myelosuppression, seizure disorder)

Miscellaneous topical ointment

Another topical product that has gained FDA approval for genital warts includes kunecatechins.

Kunecatechins (Veregen)

Botanical drug product for topical use consisting of extract from green tea leaves. Mode of action unknown but does elicit antioxidant activity in vitro. Indicated for topical treatment of external genital and perianal warts (condylomata acuminatum) in immunocompetent patients.

Dosing

Adult

Apply topically tid; use approximately a 0.5-cm strand of ointment topically for each external genital or perianal wart

Pediatric

<18 years: Not established

Interactions

None reported

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Not evaluated for urethral, intravaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions; avoid application to open wounds, eyes, and nose; wash hands before and after application; avoid sexual contact while ointment is on skin; may cause application site reactions, phimosis, inguinal lymphadenitis, urethral meatal stenosis, dysuria, genital herpes simplex, vulvitis, hypersensitivity, pruritus, pyodermitis, skin ulcer, erosions in the urethral meatus, and superinfection of warts and ulcers

Vaccines

A human papillomavirus vaccine is now available for prevention of HPV-associated dysplasias and neoplasia including cervical cancer, genital warts (condyloma acuminata), and precancerous genital lesions. The immunization series should be completed in girls and young women aged 9-26 years.

Papillomavirus vaccine (Gardasil)

Quadrivalent human papillomavirus (HPV) recombinant vaccine.
First vaccine indicated to prevent cervical cancer, genital warts (condyloma acuminata), and precancerous genital lesions (eg, cervical adenocarcinoma in situ; cervical intraepithelial neoplasia grades 1, 2, and 3; vulvar intraepithelial neoplasia grades 2 and 3; vaginal intraepithelial neoplasia grades 2 and 3) due to HPV types 6, 11, 16, and 18. Vaccine efficacy mediated by humoral immune responses following immunization series.

Dosing

Adult

<26 years: 0.5 mL IM administered as 3 separate doses; administer second and third doses 2 and 6 mo after first dose, respectively
>26 years: Not established

Pediatric

<9 years: Not established
>9 years: Administer as in adults

Interactions

Immunosuppressive therapies (eg, irradiation, antineoplastic agents, corticosteroids) may decrease immune response to vaccine

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Shake well before administering; administer in deltoid region of upper arm or in higher anterolateral thigh; individuals with impaired immune responsiveness (eg, HIV infection, neoplastic disease, currently taking immunosuppressive drugs) may not elicit antibody response; because of IM administration, do not administer to individuals with bleeding disorders (eg, thrombocytopenia, coagulation disorders, anticoagulant therapy); common adverse effects include pain, swelling, erythema, and/or pruritus at injection site and fever

Follow-up

Further Inpatient Care

• Generally, no further inpatient care is necessary unless the patient has malignant transformation of lesions to carcinoma.

Further Outpatient Care

• Patient should have a follow-up visit with OB/GYN (female) or with urology (male) within 1 week.
  • Treat patient using medications and, if ineffective, with cryotherapy, curettage, electrodesiccation, surgical excision, carbon dioxide laser treatment, or combination therapy.
  • Evaluate and treat sexual partner(s).
  • Perform workup for HPV and other STDs.
• Search for immunosuppression in patients with treatment failures and recurrences.
• Look for biopsy recurrences and treatment failures.

Inpatient & Outpatient Medications

• Podofilox (purified podophyllotoxin) is available for home use by the patient.

Deterrence/Prevention

• No medications are 100% effective. A vaccine for HPV has been recently approved by the FDA.
• Sexual abstinence and monogamy are protective.
• Condoms may discourage transmission.

Complications

• Local disfigurement
• Transformation to genitourinary malignancies in both males and females
• Transmission to neonate or partners
• Recurrence of condyloma acuminata

Prognosis

• Many patients either fail to respond to treatment or condyloma acuminata recurs after adequate response.
• Recurrence rate of cervical dysplasia in women is not altered by treatment of sexual partners.
• Recurrence rates exceed 50% after 1 year and have been attributed to the following:
  • Repeat infection from sexual contact
  • Long incubation period of HPV
  • Location of virus in superficial skin layers away from lymphatics
  • Persistence of virus in surrounding skin, hair follicles, or sites not adequately reached by intervention used
  • Missed or deep lesions
  • Subclinical lesions
  • An underlying immunosuppression

Patient Education

• Identify and educate individuals at risk for condyloma acuminata.
• For excellent patient education resources, visit eMedicine's Sexually Transmitted Diseases Center. Also, see eMedicine's patient education article Genital Warts.

Miscellaneous

Medicolegal Pitfalls

• Failure to inform patient of potential risk of malignant transformation of lesions
• Failure to indicate necessity for follow-up care, even after treatment eradicates lesions
• Failure to indicate possibility of subclinical combined with intravaginal or cervical lesions and need to search for them
• Failure to indicate treatment availability and follow-up care
• Failure to inform patient of risk of HPV transmission to sexual partners and neonates
• Failure to inform patient of necessity of treating partners
• Failure to search for immunosuppression in patients with treatment failures and recurrences

Special Concerns

• Pregnant patients
  • Latent infection may become activated with numerous large lesions.
  • Lesions often present or increase during pregnancy.
  • Lesions may make vaginal delivery difficult if in cervix, vagina, or vulva.
  • Lesions tend to bleed easily.
  • Lesions often spontaneously regress after delivery.
  • The American College of Obstetrics and Gynecology currently does not recommend cesarean sections simply due to positive HPV status.
• Pediatric patients
  • Neonates may become infected during passage through an infected birth canal.
  • Incidence of perinatal transmission to the infant pharynx is as high as 50% and occurs most frequently with HPV types 6 and 11. Incidence of genital infection in the neonate is 4%.

Multimedia

Media file 1: Genital wart in pubic area

Media file 2: Genital wart in pubic area (close-up view)

Media file 3: Genital wart in pubic area (very close-up view)

Media file 4: Genital wart in pubic area (look at bottom middle of picture)

References

1. Chan PD, Winkle PJ, Winkle CR. Condyloma acuminata. In: Current Clinical Strategies - Family Medicine. 2^nd ed. Current Clinical Strategies Publishing Inc; 1995:209-210.

2. Congilosi SM, Madoff RD. Current therapy for recurrent and extensive anal warts. Dis Colon Rectum. Oct 1995;38(10):1101-7. [Medline].

3. Friedman M, Bayer I, Letko I, Duvdevani R, Zavaro-Levy O, Ron B, et al. Topical treatment for human papillomavirus-associated genital warts in humans with the novel tellurium immunomodulator AS101: assessment of its safety and efficacy. Br J Dermatol. Sep 19 2008;[Medline].

4. Garrido JL. Human papilloma virus--H.P.V. condyloma. Current studies in diagnosis, treatment and prognosis. Clin Exp Obstet Gynecol. 1996;23(2):99-102. [Medline].

5. Hoory T, Monie A, Gravitt P, Wu TC. Molecular epidemiology of human papillomavirus. J Formos Med Assoc. Mar 2008;107(3):198-217. [Medline].

6. Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician. Dec 15 2004;70(12):2335-42. [Medline].

7. Leung AK, Kellner JD, Davies HD. Genital infection with human papillomavirus in adolescents. Adv Ther. May-Jun 2005;22(3):187-97. [Medline].

8. Mayeaux EJ, Harper MB, Barksdale W, Pope JB. Noncervical human papillomavirus genital infections. Am Fam Physician. Sep 15 1995;52(4):1137-46, 1149-50. [Medline].

9. Poolman EM, Elbasha EH, Galvani AP. Vaccination and the evolutionary ecology of human papillomavirus. Vaccine. Jul 18 2008;26 Suppl 3:C25-30. [Medline].

10. Prasad CJ. Pathobiology of human papillomavirus. Clin Lab Med. Sep 1995;15(3):685-704. [Medline].

11. Sinal SH, Woods CR. Human papillomavirus infections of the genital and respiratory tracts in young children. Semin Pediatr Infect Dis. Oct 2005;16(4):306-16. [Medline].

12. Sykes NL. Condyloma acuminatum. Int J Dermatol. May 1995;34(5):297-302. [Medline].

Keywords

condyloma acuminata, genital wart, human papillomavirus infection, HPV infection, HPV type 6, HPV-6, HPV type 11, HPV-11, bowenoid papulosis, seborrheic keratoses, Buschke-Löwenstein tumors, giant condyloma, carcinoma in situ, sexually transmitted disease, STD, genitourinary cancer, vulvar condyloma acuminata, warts of penile urethral meatus, acute urethral obstruction, smoking, oral contraceptives, multiple sexual partners, painless bumps, coital bleeding, papular eruptions, Papanicolaou tests, Pap tests

Contributor Information and Disclosures

Author

Delaram Ghadishah, MD, Staff Physician, Encino Tarzana Emergency Department
Delaram Ghadishah, MD is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians
Disclosure: Nothing to disclose.

Medical Editor

William K Chiang, MD, Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center
William K Chiang, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Barry J Sheridan, DO, Chief, Department of Emergency Medical Services, Brooke Army Medical Center
Barry J Sheridan, DO is a member of the following medical societies: American Academy of Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Barry E Brenner, MD, PhD, FACEP, Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, University Hospitals, Case Medical Center
Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)